Abstract:Background: Dysferlinopathy refers to a group of muscle diseases with progressive muscle weakness and atrophy caused by pathogenic mutations of the DYSF gene. The pathogenesis remains unknown, and currently no specific treatment is available to alter the disease progression. This research aims to investigate important biomarkers and their latent biological pathways participating in dysferlinopathy and reveal the association with immune cell infiltration. Methods: GSE3307 and GSE109178 were obtained from the Gene Expression Omnibus (GEO) database. Based on weighted gene co-expression network analysis (WGCNA) and differential expression analysis, coupled with least absolute shrinkage and selection operator (LASSO), the key genes for dysferlinopathy were identified. Functional enrichment analysis Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were applied to disclose the hidden biological pathways. Following that, the key genes were approved for diagnostic accuracy of dysferlinopathy based on another dataset GSE109178, and quantitative real-time polymerase chain reaction (qRT-PCR) were executed to confirm their expression. Furthermore, the 28 immune cell abundance patterns in dysferlinopathy were determined with single-sample GSEA (ssGSEA). Results: 1,579 differentially expressed genes (DEGs) were screened out. Based on WGCNA, three co-expression modules were obtained, with the MEskyblue module most strongly correlated with dysferlinopathy. 44 intersecting genes were recognized from the DEGs and the MEskyblue module. The six key genes MVP, GRN, ERP29, RNF128, NFYB and KPNA3 were discovered through LASSO analysis and experimentally verified later. In a receiver operating characteristic analysis (ROC) curve, the six hub genes were shown to be highly valuable for diagnostic purposes. Furthermore, functional enrichment analysis highlighted that these genes were enriched mainly along the ubiquitin-proteasome pathway (UPP). Ultimately, ssGSEA showed a significant immune-cell infiltrative microenvironment in dysferlinopathy patients, especially T cell, macrophage, and activated dendritic cell (DC). Conclusion: Six key genes are identified in dysferlinopathy with a bioinformatic approach used for the first time. The key genes are believed to be involved in protein degradation pathways and the activation of muscular inflammation. And several immune cells, such as T cell, macrophage and DC, are considered to be implicated in the progression of dysferlinopathy.

A preliminary study of gene products encoded by disease genes of muscular dystrophy

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

Clinical, Molecular Pathological and Genetic Analysis of a Chinese Family with Dystrophinopathy

Genetic Variation Analysis and Treatment Strategy of 20 Patients with Dystrophin Gene Mutations

Comprehensive Genetic Diagnosis of Patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) and Pathogenicity Analysis of Splice Site Variants in the DMD Gene

Clinical Diagnosis and Genetic Analysis of Children With Muscular Dystrophies

Differential expression profiling between the relative normal and dystrophic muscle tissues from the same LGMD patient

Clinical Features and Molecular Genetic Analysis of a Pedigree of Limb Girdle Muscular Dystrophy

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

Value of muscle magnetic resonance imaging in the differential diagnosis of muscular dystrophies related to the dystrophin-glycoprotein complex

Characteristics of Dystrophin Gene Mutations among Chinese Patients As Revealed by Multiplex Ligation–Dependent Probe Amplification

Clinical Heterogeneity and a High Proportion of Novel Mutations in a Chinese Cohort of Patients with Dysferlinopathy.

Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy

Clinical and Genetic Spectrum of Sarcoglycanopathies in a Large Cohort of Chinese Patients.

Key biomarkers and latent pathways of dysferlinopathy: Bioinformatics analysis and in vivo validation

Structural Analysis of DMD Gene and Its Clinical Application in Chinese.I.Bgl II Exon-Containing Fragment, RFLP and Carrier Detection

Abnormal Expression of Dysferlin in Blood Monocytes Supports Primary Dysferlinopathy in Patients Confirmed by Genetic Analyses

Discovery of specific mutations in spinal muscular atrophy patients by next-generation sequencing

Clinical and electrophysiological analysis of limb-girdle muscular dystrophy:A geneological report

[Application of Targeted Capture Technology and Next Generation Sequencing in Molecular Diagnosis of Inherited Myopathy].

[Clinical, Molecular Pathological and Genetic Analyses of a Chinese Family with Congenital Muscular Dystrophy Type 1A].